Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,583,516
  • Shares Outstanding, K 90,642
  • Annual Sales, $ 145,970 K
  • Annual Income, $ -204,750 K
  • 60-Month Beta 1.70
  • Price/Sales 10.49
  • Price/Cash Flow N/A
  • Price/Book 4.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.58
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.68
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.71 +18.76%
on 07/07/20
18.18 -3.91%
on 07/20/20
+1.94 (+12.49%)
since 07/02/20
3-Month
12.52 +39.54%
on 06/29/20
22.19 -21.27%
on 06/22/20
+3.09 (+21.49%)
since 05/05/20
52-Week
9.60 +81.98%
on 03/16/20
26.81 -34.84%
on 12/04/19
+1.02 (+6.20%)
since 08/05/19

Most Recent Stories

More News
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 17.47 (+3.37%)
Heron Therapeutics: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Wednesday reported a loss of $55.2 million in its second quarter.

HRTX : 17.47 (+3.37%)
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some...

HRTX : 17.47 (+3.37%)
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRTX : 17.47 (+3.37%)
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 17.47 (+3.37%)
First Week of March 2021 Options Trading For Heron Therapeutics (HRTX)

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the March 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the...

HRTX : 17.47 (+3.37%)
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 17.47 (+3.37%)
Look for Shares of Heron Therapeuti to Potentially Pullback after Yesterday's 2.09% Rise

Heron Therapeuti (NASDAQ:HRTX) traded in a range yesterday that spanned from a low of $15.78 to a high of $16.10. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

HRTX : 17.47 (+3.37%)
Heron Therapeuti Rises 1.99% on Heavy Volume: Watch For Potential Pullback

Heron Therapeuti (NASDAQ:HRTX) traded in a range yesterday that spanned from a low of $19.76 to a high of $20.10. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

HRTX : 17.47 (+3.37%)
Heron Therapeuti Up 43.4% Since SmarTrend Uptrend Call (HRTX)

SmarTrend identified an Uptrend for Heron Therapeuti (NASDAQ:HRTX) on April 8th, 2020 at $13.73. In approximately 2 months, Heron Therapeuti has returned 43.45% as of today's recent price of $19.70.

HRTX : 17.47 (+3.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade HRTX with:

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

2nd Resistance Point 18.07
1st Resistance Point 17.77
Last Price 17.47
1st Support Level 16.99
2nd Support Level 16.50

See More

52-Week High 26.81
Fibonacci 61.8% 20.24
Fibonacci 50% 18.20
Last Price 17.47
Fibonacci 38.2% 16.17
52-Week Low 9.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar